» Articles » PMID: 39565448

Functionalizing of Magnetic Nanoparticles As Nano-architecture Towards Bioimaging and Colorimetric Recognition of MCF-7 Cells: Dual Opto-sensing and Fluorescence Monitoring for Early-stage Diagnosis of Breast Cancer

Overview
Journal Mikrochim Acta
Specialties Biotechnology
Chemistry
Date 2024 Nov 20
PMID 39565448
Authors
Affiliations
Soon will be listed here.
Abstract

Considering the high incidence of breast cancer, a sensitive and specific approach is crucial for its early diagnosis and follow-up treatment. Folate receptors (FR), which are highly expressed on the epithelial tissue such as breast cancer cells (e.g., MCF-7), have been used in cancer diagnosis and bioimaging. This study presents an innovative colorimetric and fluorescence bioimaging platform towards MCF-7 using folic acid (FA)-conjugated iron-oxide magnetite silica-based nanocomposite (FeO@SiO-3-aminopropyl)triethoxysilane (APTES-NH)@cysteine (Cyt)-Cyt@FA). For identification of MCF-7, the polyvinylpyrrolidone (PVP)-capped-platinum (Pt) nanoparticle was utilized as a nanozyme to catalyze the reaction between 3,3',5,5'-tetramethylbenzidine (TMB) and HO for visual detection of MCF-7 cells. Colorimetric changes are detectable by the naked eye and spectrophotometry at the wavelength of 450 nm, with a linear range of 50-5000 cells/mL and a detection limit of 30 cells/mL. The FeO@SiO-APTES-NH@Cyt-Cyt@FA complex was modified with rhodamine B as a fluorescence bioimaging probe to monitor FR-overexpressed MCF-7 cells. The nanocomposite is biocompatible with a toxicity threshold of about 800 µg/mL. These methodologies facilitate bioimaging and colorimetric assays without sophisticated instrumentation, offering high specificity, sensitivity, repeatability, and stability, making them suitable as versatile methods for detecting and bioimaging cancer cells.

Citing Articles

Targeted co-delivery nanosystem based on methotrexate, curcumin, and PAMAM dendrimer for improvement of the therapeutic efficacy in cervical cancer.

Aghanejad A, Kheiriabad S, Ghaffari M, Namvar Aghdash S, Ghafouri N, Ezzati Nazhad Dolatabadi J Sci Rep. 2025; 15(1):1813.

PMID: 39805840 PMC: 11730290. DOI: 10.1038/s41598-024-82074-7.

References
1.
Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M . Current and future burden of breast cancer: Global statistics for 2020 and 2040. Breast. 2022; 66:15-23. PMC: 9465273. DOI: 10.1016/j.breast.2022.08.010. View

2.
Mann R, Kuhl C, Moy L . Contrast-enhanced MRI for breast cancer screening. J Magn Reson Imaging. 2019; 50(2):377-390. PMC: 6767440. DOI: 10.1002/jmri.26654. View

3.
Wang K, Fan D, Liu Y, Wang E . Highly sensitive and specific colorimetric detection of cancer cells via dual-aptamer target binding strategy. Biosens Bioelectron. 2015; 73:1-6. DOI: 10.1016/j.bios.2015.05.044. View

4.
Liu M, Zhang H, Chen S, Yu Y, Wang J . MnO-graphene oxide hybrid nanomaterial with oxidase-like activity for ultrasensitive colorimetric detection of cancer cells. Anal Bioanal Chem. 2021; 413(17):4451-4458. DOI: 10.1007/s00216-021-03399-0. View

5.
Hua X, Zhou Z, Yuan L, Liu S . Selective collection and detection of MCF-7 breast cancer cells using aptamer-functionalized magnetic beads and quantum dots based nano-bio-probes. Anal Chim Acta. 2013; 788:135-40. DOI: 10.1016/j.aca.2013.06.001. View